Patent · US Active

Methods of using anti-lap antibodies

US11230601B2 · kind B2 · utility

0Cited by
81References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 10, 2018
Grant dateJan 25, 2022
Priority date
Expiry dateOct 10, 2038

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-β1 and are characterized by particular functional features, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.